Form 8-K - Current report:
SEC Accession No. 0001104659-26-052081
Filing Date
2026-04-30
Accepted
2026-04-30 06:53:18
Documents
15
Period of Report
2026-04-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2612241d1_8k.htm   iXBRL 8-K 42334
2 EXHIBIT 99.1 tm2612241d1_ex99-1.htm EX-99.1 530575
3 EXHIBIT 99.2 tm2612241d1_ex99-2.htm EX-99.2 263490
8 GRAPHIC tm2612241d1_ex99-1img001.jpg GRAPHIC 1976
  Complete submission text file 0001104659-26-052081.txt   1130512

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20260430.xsd EX-101.SCH 4655
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20260430_def.xml EX-101.DEF 28822
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20260430_lab.xml EX-101.LAB 39661
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20260430_pre.xml EX-101.PRE 27306
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2612241d1_8k_htm.xml XML 10851
Mailing Address 126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY NJ 07065
Business Address 126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY NJ 07065 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 26919944
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)